CDMO - Avid Bioservices, Inc.
After hours:
| Previous Close | 15.58 |
| Open | 15.76 |
| Bid | 15.21 x 1000 |
| Ask | 16.00 x 1000 |
| Day's Range | 15.27 - 15.94 |
| 52 Week Range | 11.34 - 21.05 |
| Volume | |
| Avg. Volume | 598,685 |
| Market Cap | 995.75M |
| Beta (5Y Monthly) | 1.82 |
| PE Ratio (TTM) | 9.53 |
| EPS (TTM) | 1.67 |
| Earnings Date | Jun 27, 2023 - Jul 03, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 22.25 |
GlobeNewswireAvid Bioservices to Participate in RBC Capital Markets Global Healthcare Conference
TUSTIN, Calif., May 10, 2023 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced that the company will participate in the RBC Capital Markets Global Healthcare Conference. Nick Green, president and chief executive officer, will be the featured speaker
Simply Wall St.Is There An Opportunity With Avid Bioservices, Inc.'s (NASDAQ:CDMO) 47% Undervaluation?
Key Insights Using the 2 Stage Free Cash Flow to Equity, Avid Bioservices fair value estimate is US$34.95 Avid...
- Simply Wall St.
Improved Earnings Required Before Avid Bioservices, Inc. (NASDAQ:CDMO) Shares Find Their Feet
When close to half the companies in the United States have price-to-earnings ratios (or "P/E's") above 16x, you may...
- GlobeNewswire
Avid Bioservices Unveils Completed Mammalian Cell Facilities Expansion Providing Significantly Increased Capacity for Existing and Future Customers
Company to Host Open House to Celebrate Official Launch of Newest CGMP Mammalian Cell Manufacturing Suites within Myford Facility First Customer Project in Newly Expanded Capacity to Kick-Off This Month Company Also Announces Completion of Mammalian Cell Process Development Capacity Expansion TUSTIN, Calif., April 04, 2023 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by
Motley FoolWhy Avid Bioservices Stock Is Surging Today
Shares of the contract development and manufacturing organization Avid Bioservices (NASDAQ: CDMO) were up by a healthy 34% on heavy volume as of 11 a.m. ET Tuesday. After this double-digit move higher, the bio-manufacturing company's stock is now trading at 6.5 times 2024 estimated sales.
- Simply Wall St.
Declining Stock and Solid Fundamentals: Is The Market Wrong About Avid Bioservices, Inc. (NASDAQ:CDMO)?
Avid Bioservices (NASDAQ:CDMO) has had a rough month with its share price down 16%. However, a closer look at its sound...
- Thomson Reuters StreetEvents
Q3 2023 Avid Bioservices Inc Earnings Call
Q3 2023 Avid Bioservices Inc Earnings Call
ZacksAvid Bioservices (CDMO) Q3 Earnings and Revenues Top Estimates
Avid Bioservices (CDMO) delivered earnings and revenue surprises of 275% and 5.61%, respectively, for the quarter ended January 2023. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Avid Bioservices Reports Financial Results for Third Quarter Ended January 31, 2023, and Recent Developments
-- Recorded Third Quarter Revenue of $38.0 Million, a 21% Increase Compared to Prior Year Quarter -- -- Signed $67 Million in Net New Business Orders Resulting in a Backlog of $176 million, an Increase of 26% Year-Over-Year -- -- Mammalian Cell Manufacturing is Now Online and Process Development Facility Expansions to be Online by End of Calendar Q1 2023, Adding Approximately $120 Million of Revenue Capacity -- -- Cell and Gene Therapy Facility Expansion Expected to be Online by End of Calendar
ZacksSteer Clear Of These 4 Toxic Stocks to Avoid Losses
Correctly spotting overpriced stocks and shunning them at the right time may avoid portfolio bleeding. ILMN, LTRX, BSY and CDMO are a few such toxic stocks.
- GlobeNewswire
Avid Bioservices to Report Financial Results for Third Quarter of Fiscal Year 2023 After Market Close on March 13, 2023
TUSTIN, Calif., March 06, 2023 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality services to biotechnology and pharmaceutical companies, today announced that it will report financial results for the third quarter of fiscal year 2023 on March 13, 2023, after market close and will host a webcast at 1:30 PM Pacific Time (4:30 PM Eastern Time). Members o
- Simply Wall St.
Avid Bioservices Second Quarter 2023 Earnings: Revenues Beat Expectations, EPS Lags
Avid Bioservices ( NASDAQ:CDMO ) Second Quarter 2023 Results Key Financial Results Revenue: US$34.8m (up 33% from 2Q...
ZacksAvid Bioservices (CDMO) Reports Q2 Loss, Tops Revenue Estimates
Avid Bioservices (CDMO) delivered earnings and revenue surprises of 0% and 12.12%, respectively, for the quarter ended October 2022. Do the numbers hold clues to what lies ahead for the stock?
- Thomson Reuters StreetEvents
Edited Transcript of CDMO.OQ earnings conference call or presentation 6-Dec-22 9:30pm GMT
Q2 2023 Avid Bioservices Inc Earnings Call
- GlobeNewswire
Avid Bioservices Reports Financial Results for Second Quarter Ended October 31, 2022 and Recent Developments
-- Recorded Second Quarter Revenue of $34.8 Million -- -- Signed $26 Million in Net New Business Orders Resulting in a Backlog of $147 Million, an Increase of 23% Year-Over-Year -- -- Mammalian Cell Facilities and Cell and Gene Therapy Facility Expansions Continue on Schedule -- -- Revenue Guidance for Fiscal 2023 Increased to $145 to $150 Million -- TUSTIN, Calif., Dec. 06, 2022 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturin
- GlobeNewswire
Avid Bioservices to Report Financial Results for Second Quarter of Fiscal Year 2023 After Market Close on December 6, 2022
TUSTIN, Calif., Nov. 29, 2022 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality services to biotechnology and pharmaceutical companies, today announced that it will report financial results for the second quarter of fiscal year 2023 on December 6, 2022 after market close and will host a webcast at 1:30 PM Pacific Time (4:30 PM Eastern Time). Members
- Simply Wall St.
Avid Bioservices (NASDAQ:CDMO) jumps 12% this week, though earnings growth is still tracking behind five-year shareholder returns
Avid Bioservices, Inc. ( NASDAQ:CDMO ) shareholders might be concerned after seeing the share price drop 23% in the...
- GlobeNewswire
Avid Bioservices Appoints Oksana Lukash as Vice President, People
TUSTIN, Calif., Nov. 16, 2022 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced the appointment of Oksana Lukash, as vice president, people. Ms. Lukash has more than 20 years of human resources experience with both established and entrepreneurial org
- GlobeNewswire
Avid Bioservices to Participate in the Credit Suisse 31st Annual Healthcare Conference
TUSTIN, Calif., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced that the company will participate in the Credit Suisse 31st Annual Healthcare Conference. Nick Green, president and chief executive officer of Avid Bioservices, will deli
ZacksDoes Avid Bioservices (CDMO) Have the Potential to Rally 61% as Wall Street Analysts Expect?
The consensus price target hints at a 60.5% upside potential for Avid Bioservices (CDMO). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
GlobeNewswireTOMI to Install Custom Engineered Integrated iHP System in Avid Bioservices, Inc. Viral Vector Manufacturing Facility in California
FREDERICK, Md/, Oct. 10, 2022 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global company specializing in disinfection and decontamination, utilizing its premier Binary Ionization Technology (BIT) platform through its SteraMist products - a hydrogen peroxide-based mist and fog composed of ionized Hydrogen Peroxide (iHP), today announced that it has recently received a purchase order for an iHP Custom Engineered System (CES) from Avid Bioservices, Inc. (Avid)
- Simply Wall St.
Are Strong Financial Prospects The Force That Is Driving The Momentum In Avid Bioservices, Inc.'s NASDAQ:CDMO) Stock?
Most readers would already be aware that Avid Bioservices' (NASDAQ:CDMO) stock increased significantly by 17% over the...
- GlobeNewswire
Avid Bioservices to Participate in RBC Global CDMO Conference
TUSTIN, Calif., Sept. 27, 2022 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced that the company will participate in the RBC Global CDMO Conference. Nick Green, president and chief executive officer, will be the featured speaker in a fireside chat a
- GlobeNewswire
Avid Bioservices Appoints Michael Alston, Jr. as Vice President, Operations
Accomplished Operations Professional Promoted from Role as Director of Project Engineering; Credited with Leading All of the Company’s Ongoing Facility Expansion ProjectsTUSTIN, Calif., Sept. 22, 2022 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced
- Simply Wall St.
We Ran A Stock Scan For Earnings Growth And Avid Bioservices (NASDAQ:CDMO) Passed With Ease
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...